WebHeader_Grove.png
Play Live Radio
Next Up:
0:00
0:00
Available On Air Stations
Support the news you rely on from NHPR and NPR with a gift today!

Moderna and Flagship Pioneering: Noubar Afeyan

Noubar Afeyan is co-founder of Moderna.
Kristen Uroda for NPR

In the field of bio-tech, it can take 10 years and millions of dollars to see if an experimental idea might turn into a life-saving treatment—if it ever does. Noubar Afeyan fully understood those risks when he co-founded Moderna in 2010. He and his colleagues were looking for a way to deploy the messenger RNA molecule to tackle life-threatening diseases.

In January of 2020, an urgent opportunity presented itself in the form of a deadly virus that was spreading across the globe. At a breathtaking pace, Moderna produced a prototype for a COVID-19 vaccine, partnered with the NIH to test it, and produced millions of doses, becoming part of the most rapid vaccine roll-out in human history.

While Moderna is the best known of Noubar's companies, he has launched many others in the bio-tech space as part of Flagship Pioneering, his multi-billion dollar venture studio.

Copyright 2022 NPR. To see more, visit https://www.npr.org.

You make NHPR possible.

NHPR is nonprofit and independent. We rely on readers like you to support the local, national, and international coverage on this website. Your support makes this news available to everyone.

Give today. A monthly donation of $5 makes a real difference.